Assessment of efficacy and complication of morphine and naloxan in renal colic

Comparative assessment of analgesic and complications of intravenous morphine and placebo with intravenous naloxon and morphine in renal colic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106146804N1

Enrollment

300

Registered

2011-12-17

Start date

2011-12-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic. Unspecified renal colic

Interventions

Intervention 1: 150 renal colic patients in group B (intervention group), with 18-69 years old age and Pain score, equal or more than 40 or 4 in VAS or NRS system, respectively, will receive 1 CC of l

with 18-69 years old age and Pain score, equal or more than 40 or 4 in VAS or NRS system, respectively, will receive 1 cc saline as placebo intravenously. 5 minutes later,this group will receive 2.5 m

Treatment - Drugs

150 renal colic patients in group B (intervention group), with 18-69 years old age and Pain score, equal or more than 40 or 4 in VAS or NRS system, respectively, will receive 1 CC of low dose naloxone

150 renal colic patients in Group A (control group)

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include : age 18-69 years old; Pain score equal or more than 40 or 4 in VAS or NRS system, respectively; and Exclusion criteria include: Pyelonephritis or fever equal or more than 38 degree centigrade; History of addiction or opioid allergy;History of cardiovascular disease (function class 3-4 or decompensated CHF or uncontrolled hypertension) ; History of active hepatobiliary disorders ; Hemodinamically unstable patients (BP below 90mmHg or MAP decreased more than 30% baseline) ;Pregnancy and Breast feeding and History of CVA in last 2 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: Every 15 min during 90 min. Method of measurement: Questionaire,according to VAS or NRS pain score systems.	—

Secondary

Measure	Time frame
Side effects. Timepoint: Every 15 min during 90 min. Method of measurement: Questionaire,according to physical examination and patients observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Javad Behzadnia

Baghyatallah Medical Sciences University

Behzadnia@bmsu.ac.ir+98 21 2277 4528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026